GHK-Cu, also called copper tripeptide-1, is a small peptide bound to copper that is used in skin-care research.2,5 None of the sources reviewed here reports an FDA approval of GHK-Cu. Since May 2026, FDA has listed GHK-Cu, except in injected forms, as under evaluation for the list of substances pharmacies may use in compounding.1 FDA lists injected GHK-Cu among compounding substances that may present significant safety risks, noting possible immune reactions and limited human data.3 GHK-Cu is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.7
GHK-Cu at a glance
What it is
A copper-binding tripeptide, a chain of three amino acids (glycyl-histidyl-lysine) bound to copper, recorded by FDA as copper tripeptide-1.2,4
FDA status
No FDA approval is reported in the sources reviewed here. FDA lists GHK-Cu, except in injected forms, in category 1 (under evaluation) for the 503A compounding list, and lists injected GHK-Cu among withdrawn nominations with safety concerns.1,3
Human evidence
Two randomized studies of copper-peptide skin and wound products, one of them very small, with mixed results.4,5
Evidence strength
Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned
What is GHK-Cu?
GHK-Cu is a complex of copper with a three-amino-acid peptide, glycyl-L-histidyl-L-lysine. FDA’s substance registry records it as copper tripeptide-1.2,4
Published human studies have tested it in wound-care and skin-care products.4,5
How is GHK-Cu thought to work?
GHK-Cu has been studied for wound healing and skin repair, but the sources reviewed here do not establish how it works in people.4,5
FDA’s safety-risk page notes that injected GHK-Cu could provoke immune reactions because of possible clumping of the peptide and peptide-related impurities.3
What do human studies show?
In a multicenter randomized study in people with diabetic foot ulcers, the authors reported greater ulcer closure and fewer infections with a copper-peptide gel than with an inactive gel in one comparison. The abstract does not give the total number of participants.4
In a small randomized study after laser skin resurfacing, 13 people completed 12 weeks of skin care with or without GHK-Cu. Blinded and computer assessments found no significant differences in redness, wrinkles or overall skin quality, although participants rated their skin better with GHK-Cu.5
FDA states that there are limited human data to inform the safety of injected GHK-Cu.3
What the evidence base contains
Controlled human trial A multicenter, randomized, evaluator-blinded study comparing a copper-peptide gel with an inactive gel, alongside standard wound care, in people with diabetic foot ulcers. The published abstract does not give the total number of participants.4
Controlled human trial A small randomized study in which 13 people completed skin-care routines with or without GHK-Cu after laser skin resurfacing and were followed for 12 weeks.5
None of the sources reviewed here reports an approval of GHK-Cu by FDA. FDA’s records reviewed here concern its status for pharmacy compounding.1,3
FDA’s list of substances nominated under section 503A, updated May 14, 2026, places GHK-Cu, except in injected forms, back in category 1, meaning under evaluation. FDA explains that it had removed GHK-Cu on April 22, 2026 after nominations were withdrawn, but that one nominator clarified on May 5, 2026 that it meant to withdraw only the injected form.1
The same list states that FDA intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about whether GHK-Cu should be added to the 503A bulks list.1
FDA’s compounding safety-risk page, current as of April 22, 2026, lists injected GHK-Cu among substances whose nominations were withdrawn, citing possible immune reactions and limited human safety data.3
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHK-Cu is not among them.6,7
Timeline
Results of a randomized study of a copper-peptide gel in diabetic foot ulcers are published.4
Results of a small randomized study of GHK-Cu skin care after laser resurfacing are published.5
FDA removes GHK-Cu from category 1 after nominations are withdrawn, and its safety-risk page lists injected GHK-Cu among withdrawn nominations.1,3
FDA restores GHK-Cu, except in injected forms, to category 1 of its 503A nominations list.1
What is still unknown?
Whether GHK-Cu has a clinical benefit: the two randomized studies reviewed here had mixed results, and one was very small.4,5
The safety of injected GHK-Cu, for which FDA says human data are limited.3
What FDA will decide after consulting its advisory committee, which it said it intends to do before the end of February 2027.1
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for GHK-Cu: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for GHK-Cu are the records PeptideScanner has selected and published, not every registration or paper about GHK-Cu. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
Not FDA-approved; under FDA review for pharmacy compounding by non-injectable routes. Two randomized studies of copper-peptide skin and wound products report mixed results. FDA lists injected GHK-Cu among substances that may present significant safety risks. GHK-Cu is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗
Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
Three selected human reports cover topical wound and post-laser skin care, plus a multi-ingredient intradermal hair formulation containing copper tripeptide-1. Formulation and route are kept separate. This is not an exhaustive review of GHK or GHK-Cu.↗↗↗
What the reviewed sources report
The selected topical studies had different findings: the ulcer study reported improved closure, while the small post-laser study found no objective advantage in erythema or skin appearance. The uncontrolled hair study cannot attribute changes to GHK-Cu alone or establish the safety of other injected formulations.↗↗↗
What remains unresolved?
Which outcomes are supported by adequately controlled studies of a clearly identified GHK-Cu formulation?↗↗↗
How do route, co-ingredients, study size, and follow-up limit what can be concluded about benefits and harms?↗↗↗
Three selected human reports cover topical wound and post-laser skin care, plus a multi-ingredient intradermal hair formulation containing copper tripeptide-1. Formulation and route are kept separate. This is not an exhaustive review of GHK or GHK-Cu.123
Bottom line from this bounded source set
The selected topical studies had different findings: the ulcer study reported improved closure, while the small post-laser study found no objective advantage in erythema or skin appearance. The uncontrolled hair study cannot attribute changes to GHK-Cu alone or establish the safety of other injected formulations.123
A multicenter randomized, evaluator-blinded study compared a topical copper-peptide gel with vehicle alongside standardized wound care.1
Population
The report concerns patients with diabetic neuropathic ulcers; the PubMed abstract does not state the total sample size.1
Outcomes reported
The authors reported greater plantar-ulcer area closure and fewer infections in a selected immediate-treatment comparison. These are results for the studied topical formulation and wound-care setting.1
Limitations
Subgroup and treatment-timing comparisons require full-text assessment. The abstract alone does not establish overall healing benefit, general safety, or effectiveness by other routes.1
Reviewed study record
Post-laser skin care: small randomized comparison
Design
Patients receiving carbon-dioxide laser resurfacing were randomized to skin-care regimens with or without GHK-Cu.2
Population
Thirteen patients completed the study; outcomes were assessed through 12 weeks.2
Outcomes reported
Blinded and computer assessments found no significant between-group improvement in erythema resolution, wrinkles, or overall skin quality. Patient-reported skin-quality improvement favored the GHK-Cu regimen.2
Limitations
The sample was small, and subjective and objective findings differed. These findings do not establish a general anti-aging effect or apply to injectable use.2
Reviewed study record
Hair research: multi-ingredient formulation
Design
An open-label, single-arm pilot evaluated an intradermal formulation containing several growth factors and copper tripeptide-1.3
Population
The authors reported treating 1,000 patients with hair loss.3
Outcomes reported
The report described improvements in hair assessments and patient impressions and reported that treatment was well tolerated.3
Limitations
There was no control group and the formulation contained multiple active ingredients. The study cannot isolate a GHK-Cu effect or establish safety for GHK-Cu injections alone.3
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1046/j.1524-475x.1994.20406.x. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1001/archfaci.8.4.252. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1080/14764172.2018.1439965. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
The May 14, 2026 nominations list restores GHK-Cu excluding injectable routes to Category 1, meaning under evaluation. FDA explains that a nominator clarified its withdrawal applied only to the injectable route. FDA PDF pp. 1, 2, 3 ↗
More findings and the sources behind them
Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Earlier dated FDA and registry findings remain separately attributed below.
Injectable concerns remain separately documented
FDA’s safety page lists injectable GHK-Cu among withdrawn nominations, with concerns about aggregation, peptide impurities and immune responses, and limited human safety data. It should not be described as currently in Category 2 on that basis. FDA source ↗
What the next review could clarify
The May list announces an intention to consult the advisory committee before the end of February 2027 about potential inclusion on the 503A bulks list. An announced consultation is not a completed review or a finding of effectiveness. FDA PDF pp. 1, 2, 3 ↗
A registered topical wound study is now identifiable
NCT07437586 describes a phase 2 study of topical GHK-Cu gel in healthy adults. In the February 27, 2026 registry update it is recruiting, with estimated enrollment of 60 and no posted summary results. NCT07437586 ↗
The comparison is within each participant
Each participant is to have two standardized wounds, one assigned to GHK-Cu gel and one to vehicle gel. This paired design means wound counts are not counts of independent people; it is not an injectable study. NCT07437586 ↗
The primary endpoint is complete wound closure
The registered primary outcome is time to complete re-epithelialization, assessed through day 21 using blinded examination and photographs. The entry describes what investigators plan to measure, not an observed acceleration of healing. NCT07437586 ↗
The selected population excludes impaired-healing conditions
The trial excludes diabetes, peripheral vascular disease and other conditions that could impair wound healing. Even eventual positive results in this population would not automatically establish benefit in chronic ulcers or with injected GHK-Cu. NCT07437586 ↗
What remains to be checked
Check later results and eligibility changes for NCT07437586; registration alone is not a clinical finding.
Appraise topical human reports and FDA follow-up separately from injectable claims and product mixtures.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
306 retrieved · 3 included · 0 excluded · 303 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"GHK-Cu"[Title/Abstract] OR "GHK"[Title/Abstract] OR "copper tripeptide"[Title/Abstract] OR "glycyl-l-histidyl-l-lysine copper"[Title/Abstract] OR "glycyl-l-histidyl-l-lysine"[Title/Abstract] OR "Copper tripeptide-1"[Title/Abstract] OR "GHK copper"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
GHK, copper complexes, sequence names and topical mixtures require separate identity and formulation decisions. A name hit is not evidence of injected GHK-Cu use.
Showing 25 of 306 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 29482481 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: ghk-cu-PMID29482481-registry-linkage-unresolved.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 16847171 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: ghk-cu-PMID16847171-registry-linkage-unresolved.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 17147644 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: ghk-cu-PMID17147644-registry-linkage-unresolved.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 42712263 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42635865 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42619529 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42586657 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42578445 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42575238 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42573538 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42510549 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42404628 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42354780 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42320090 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42245779 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42193036 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42185208 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42123471 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42084774 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42058630 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42047624 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42041438 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42032121 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42021992 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42016822 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
2 retrieved · 0 included · 0 excluded · 2 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"GHK-Cu" OR "Copper tripeptide-1" OR "GHK copper" OR "glycyl-l-histidyl-l-lysine copper"
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT07437586 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07706361 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of GHK-Cu?
Not FDA-approved; under FDA review for pharmacy compounding by non-injectable routes. Two randomized studies of copper-peptide skin and wound products report mixed results. FDA lists injected GHK-Cu among substances that may present significant safety risks. GHK-Cu is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
PubMed bibliography
Publication composition
5 of 17 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 5Review 2
Bibliography fields unavailable here for 12 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
17
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsSource records by collection · 17 dated records
We added a plain-language reader guide with cited answers, re-checked FDA’s May 2026 503A nominations list, added FDA’s compounding safety-risk page and two randomized studies from our human evidence review, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include GHK-Cu.
PubMed lists PMID 42797253 in Pharmaceutics as Journal Article, Review, with publication-date metadata of 2026-08-27 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 31815212 in ACS omega as Journal Article, with publication-date metadata of 2019-11-19 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Selected records span June 2, 2015 to September 29, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PubMed lists PMID 42797253 in Pharmaceutics as Journal Article, Review, with publication-date metadata of 2026-08-27 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42510549 at 2026-08-10T10:49:10.805Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 39451062 at 2026-08-10T18:13:36.036Z. PubMed recorded a metadata revision date of 2026-07-20 and an Entrez history date of 2024-10-25. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42084774 at 2026-08-10T18:13:48.846Z. PubMed recorded a metadata revision date of 2026-07-16 and an Entrez history date of 2026-05-05. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41997403 at 2026-08-10T18:13:46.888Z. PubMed recorded a metadata revision date of 2026-07-15 and an Entrez history date of 2026-04-17. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42041438 at 2026-08-10T18:13:48.795Z. PubMed recorded a metadata revision date of 2026-07-15 and an Entrez history date of 2026-04-27. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42245779 at 2026-07-30T16:14:18.092Z. PubMed recorded a metadata revision date of 2026-06-29 and an Entrez history date of 2026-06-05. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 37062921 at 2026-07-30T16:31:12.094Z. PubMed recorded a metadata revision date of 2026-01-27 and an Entrez history date of 2023-04-17. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.↗
PubMed lists PMID 39795193 in Molecules (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2025-01-01 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 37830186 in The Journal of organic chemistry as Journal Article, with publication-date metadata of 2023-10-13 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 37896245 in Pharmaceutics as Journal Article, with publication-date metadata of 2023-10-18 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 31815212 in ACS omega as Journal Article, with publication-date metadata of 2019-11-19 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗